Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

IHH Healthcare's subsidiary, NTK, accuses Daiichi Sankyo of damaging its interests through misleading statements regarding ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) (OTCPK:DSKYF) announced Thursday the voluntary withdrawal of their U.S.

Merck & Co Inc. (MRK) and Daiichi Sankyo on Thursday said that the companies have withdrawn their application to the U.S.

Daiichi Sankyo and MSD have voluntarily withdrawn the biologics licence application (BLA) in the US for their HER3-directed ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

NTK accuses Daiichi Sankyo of misleading statements, causing damage in Fortis Healthcare open offer. JPY 200 billion damages ...

In the release, the Japanese drugmaker said NTK’s claims that it interfered with the latter’s open offer are “without any ...

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in ...

Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: ...

Northern TK Venture, a subsidiary of IHH Healthcare, has increased its legal claim against Daiichi Sankyo. The claim is now ...